Joshua Schimmer
Stock Analyst at Cantor Fitzgerald
(1.34)
# 2,742
Out of 4,831 analysts
25
Total ratings
52.94%
Success rate
-9.25%
Average return
Main Sectors:
Stocks Rated by Joshua Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $1.32 | +3,687.88% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $45.27 | +10.45% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $96.99 | -5.14% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $29.88 | -33.07% | 1 | Mar 31, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $116.87 | +11.23% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $14.26 | +250.63% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $33.37 | -25.08% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $6.62 | +1,033.79% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $90 → $100 | $59.78 | +67.28% | 1 | Mar 1, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | n/a | $574.16 | - | 2 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $1,720 → $2,000 | $3.31 | +60,322.96% | 2 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $60.81 | +39.78% | 3 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.32
Upside: +3,687.88%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $45.27
Upside: +10.45%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $96.99
Upside: -5.14%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $29.88
Upside: -33.07%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $116.87
Upside: +11.23%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $14.26
Upside: +250.63%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $33.37
Upside: -25.08%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $6.62
Upside: +1,033.79%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90 → $100
Current: $59.78
Upside: +67.28%
Regeneron Pharmaceuticals
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $574.16
Upside: -
Feb 3, 2020
Upgrades: Outperform
Price Target: $1,720 → $2,000
Current: $3.31
Upside: +60,322.96%
May 31, 2018
Assumes: Overweight
Price Target: $85
Current: $60.81
Upside: +39.78%